Ascendis Pharma shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a $180 price target.
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma shares rose following an upgrade by Oppenheimer from Perform to Outperform, with a new price target of $180.
September 05, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendis Pharma's stock received a boost after Oppenheimer upgraded it to Outperform and set a price target of $180.
The upgrade from Oppenheimer is likely to positively influence investor sentiment and drive the stock price higher in the short term. The new price target of $180 suggests significant upside potential, which can attract more buyers.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100